CT-P43 not checked

Celltrion

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“CT-P43, 45 mg in 0.5 ml, a single subcutaneous (SC) injection via pre-filled syringe (PFS)”In the company’s words, NCT06951828 on ClinicalTrials.gov
Tested for
Psoriasis
Main trialPhase 3
“This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.”In the company’s words, NCT04673786 on ClinicalTrials.gov
Copy of
Stelara (Centocor Ortho Biotech Inc)Tested side by side with the original in NCT04428814, NCT04673786

Other drugs for Psoriasis

All 41 drugs for Psoriasis

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Completed 4 Aug 2021 A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
Phase 1Completed 24 Feb 2021 Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects
Phase 1Completed 26 Nov 2025 A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CT-P43

Following is part of Solo: you see every change to CT-P43 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in